Deal Snapshot
Kalytera Therapeutics to Acquire COVID-19 Drug Developer Salzman Group
Wednesday 20 May 2020

US-based pharmaceutical company Kalytera Therapeutics, Inc. (TSX Venture: KLY) (OTCQB: KALTF) has signed a binding letter of intent to acquire US-based drug developer Salzman Group, Inc., the company said.

Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of use patents in approximately 40 countries, including the US, Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.

Date Published: 20/05/2020